Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS – Get Free Report)’s share price fell 7.1% during trading on Monday. The stock traded as low as $10.73 and last traded at $10.7540. Approximately 1,148,060 shares were traded during trading, a decline of 66% from the average daily volume of 3,398,678 shares. The stock had previously closed at $11.57.
Wall Street Analyst Weigh In
Several equities analysts recently issued reports on the stock. BTIG Research boosted their target price on shares of Compass Pathways from $14.00 to $25.00 and gave the company a “buy” rating in a research note on Tuesday, July 7th. Wells Fargo & Company assumed coverage on shares of Compass Pathways in a research note on Monday, July 27th. They set an “equal weight” rating and a $13.00 target price on the stock. Compass Point set a $25.00 target price on Compass Pathways in a research report on Tuesday, July 7th. Wolfe Research restated an “outperform” rating on shares of Compass Pathways in a research note on Tuesday, July 7th. Finally, Oppenheimer reaffirmed an “outperform” rating on shares of Compass Pathways in a report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $23.36.
Check Out Our Latest Stock Analysis on Compass Pathways
Compass Pathways Trading Down 23.2%
The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.30 and a current ratio of 1.30. The stock has a market cap of $1.23 billion, a price-to-earnings ratio of -1.92 and a beta of 2.43. The company has a 50 day moving average of $12.91 and a 200-day moving average of $10.38.
Compass Pathways (NASDAQ:CMPS – Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($1.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($1.49). On average, research analysts anticipate that Compass Pathways PLC Sponsored ADR will post -1.26 earnings per share for the current year.
Institutional Investors Weigh In On Compass Pathways
A number of institutional investors have recently added to or reduced their stakes in CMPS. Ancora Advisors LLC acquired a new stake in shares of Compass Pathways in the 2nd quarter worth approximately $43,000. EverSource Wealth Advisors LLC raised its holdings in Compass Pathways by 67.7% during the first quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company’s stock worth $26,000 after purchasing an additional 1,920 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Compass Pathways during the third quarter worth $85,000. Parallel Advisors LLC grew its holdings in Compass Pathways by 8,450.6% in the first quarter. Parallel Advisors LLC now owns 7,268 shares of the company’s stock valued at $40,000 after purchasing an additional 7,183 shares during the last quarter. Finally, North Star Investment Management Corp. grew its holdings in Compass Pathways by 23.9% in the third quarter. North Star Investment Management Corp. now owns 9,317 shares of the company’s stock valued at $116,000 after purchasing an additional 1,800 shares during the last quarter. Hedge funds and other institutional investors own 46.19% of the company’s stock.
About Compass Pathways
Compass Pathways plc is a biotechnology company developing novel treatments for mental health conditions. The company’s lead investigational product is COMP360, a proprietary formulation of synthetic psilocybin administered with psychological support in a controlled clinical setting.
Compass Pathways has focused primarily on treatment-resistant depression, a condition in which patients do not respond adequately to existing therapies. Its research programs have included mid- and late-stage clinical trials designed to evaluate the safety and effectiveness of COMP360, as well as studies exploring its potential use in other mental health disorders.
Founded in 2016 and headquartered in London, Compass Pathways conducts research and clinical development activities across the United States, the United Kingdom and other international markets.
Featured Stories
- Five stocks we like better than Compass Pathways
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid
Receive News & Ratings for Compass Pathways Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Pathways and related companies with MarketBeat.com's FREE daily email newsletter.
